Johnson & Johnson
Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
JNJ Key Statistics
Stock Snapshot
With a market cap of 467.02B, Johnson & Johnson(JNJ) trades at $194.25. The stock has a price-to-earnings ratio of 18.71 and currently yields dividends of 2.6%.
On 2025-11-12, Johnson & Johnson(JNJ) stock traded between a low of $188.60 and a high of $194.26. Shares are currently priced at $194.25, which is +3.0% above the low and -0.0% below the high.
Johnson & Johnson(JNJ) shares are trading with a volume of 7.47M, against a daily average of 7.27M.
In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $194.48 and a 52-week low of $140.68.
In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $194.48 and a 52-week low of $140.68.
JNJ News
The latest tally of analyst opinions from the major brokerage houses shows that among the 30 stocks making up the Dow Jones Industrial Average, Johnson & Johnso...
Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our P/B Growth Investor mod...
Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Shareholder Yield Inves...
Analyst ratings
56%
of 27 ratingsMore JNJ News
(RTTNews) - Johnson & Johnson (JNJ) on Thursday announced that the U.S. Food and Drug Administration (FDA) has approved Caplyta as an add-on therapy with antide...
Johnson & Johnson announced that the U.S. FDA approved Caplyta as an adjunctive therapy with antidepressants for the treatment of major depressive disorder in a...
BTIG lowered the firm’s price target on Zimmer Biomet (ZBH) to $112 from $122 and keeps a Buy rating on the shares following disappointing Q3 results. The firm...